InvestorsHub Logo
Followers 13
Posts 265
Boards Moderated 0
Alias Born 02/17/2021

Re: None

Sunday, 03/07/2021 11:18:09 AM

Sunday, March 07, 2021 11:18:09 AM

Post# of 233768
The FDA has acknowledged that with improvements to standard of care that 28 days is not sufficient to judge mortality benefit. The FDA is now recommending that trials follow patients for 60 days.

Like Cytodyn, RLF-100’s trial just concluded a few weeks ago. They were able to add the words “60 days” to their primary endpoint and are reviewing that data now. Why can’t Cytodyn do the same? Wouldn’t they be more likely to be statistically significant at 60 days? Wouldn’t that help with the other points as well?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News